These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2033428)

  • 1. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.
    Vriesendorp HM; Herpst JM; Germack MA; Klein JL; Leichner PK; Loudenslager DM; Order SE
    J Clin Oncol; 1991 Jun; 9(6):918-28. PubMed ID: 2033428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.
    Herpst JM; Klein JL; Leichner PK; Quadri SM; Vriesendorp HM
    J Clin Oncol; 1995 Sep; 13(9):2394-400. PubMed ID: 7666099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of Hodgkin's disease after indium-111 and yttrium-90 labeled antiferritin administration.
    Vriesendorp HM; Quadri SM; Andersson BS; Wyllie CT; Dicke KA
    Cancer; 1997 Dec; 80(12 Suppl):2721-7. PubMed ID: 9406730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease.
    Vriesendorp HM; Morton JD; Quadri SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5888s-5892s. PubMed ID: 7493365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease.
    Vriesendorp HM; Herpst JM; Leichner PK; Klein JL; Order SE
    Int J Radiat Oncol Biol Phys; 1989 Oct; 17(4):815-21. PubMed ID: 2674084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.
    Klein JL; Nguyen TH; Laroque P; Kopher KA; Williams JR; Wessels BW; Dillehay LE; Frincke J; Order SE; Leichner PK
    Cancer Res; 1989 Nov; 49(22):6383-9. PubMed ID: 2553255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease.
    Lai J; Quadri SM; Borchardt PE; Harris L; Wucher R; Askew E; Schweichel L; Vriesendorp HM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3315s-3323s. PubMed ID: 10541380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
    Decaudin D; Levy R; Lokiec F; Morschhauser F; Djeridane M; Kadouche J; Pecking A
    Anticancer Drugs; 2007 Jul; 18(6):725-31. PubMed ID: 17762404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolabeled immunoglobulin therapy in patients with Hodgkin's disease.
    Vriesendorp HM; Quadri SM
    Cancer Biother Radiopharm; 2000 Oct; 15(5):431-45. PubMed ID: 11155816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.
    Leichner PK; Yang NC; Frenkel TL; Loudenslager DM; Hawkins WG; Klein JL; Order SE
    Int J Radiat Oncol Biol Phys; 1988 May; 14(5):1033-42. PubMed ID: 2834309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of reagents for human radioimmunotherapy.
    Vriesendorp HM; Quadri SM; Stinson RL; Onyekwere OC; Shao Y; Klein JL; Leichner PK; Williams JR
    Int J Radiat Oncol Biol Phys; 1992; 22(1):37-45. PubMed ID: 1727128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.
    Order SE; Stillwagon GB; Klein JL; Leichner PK; Siegelman SS; Fishman EK; Ettinger DS; Haulk T; Kopher K; Finney K
    J Clin Oncol; 1985 Dec; 3(12):1573-82. PubMed ID: 2415692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.
    Bierman PJ; Vose JM; Leichner PK; Quadri SM; Armitage JO; Klein JL; Abrams RA; Dicke KA; Vriesendorp HM
    J Clin Oncol; 1993 Apr; 11(4):698-703. PubMed ID: 8478663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The theoretical implications and experimental and clinical results of radiolabeled antiferritin.
    Order SE
    Acta Oncol; 1990; 29(6):689-94. PubMed ID: 2223137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease.
    Vriesendorp HM; Quadri SM; Wyllie CT; Lai J; Borchardt PE; Harris L; Wucher R; Askew E; Schweichler L
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3324s-3329s. PubMed ID: 10541381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.